Company profile: Apexigen
1.1 - Company Overview
Company description
- Provider of clinical-stage immuno-oncology antibody therapeutics for cancer, including sotigalimab (PYX-107), a Phase 2 CD40 agonist with demonstrated anti-cancer activity in patients who have progressed on PD-(L)1 inhibitors, and the APXiMAB platform for generating novel antibodies optimized for targeted payload delivery in antibody-drug conjugates.
Products and services
- APXiMAB Platform: Custom-engineered platform that generates novel antibodies optimized for targeted payload delivery in antibody-drug conjugates, enabling precise payload targeting within ADC applications
- Sotigalimab (PYX-107): Phase 2 CD40 agonist antibody with demonstrated anti-cancer activity, particularly in patients who have progressed on PD-(L)1 inhibitors
- Immuno-oncology Antibody Discovery and Development: Clinical-stage capability that architects new antibody therapeutics for oncology designed to harness patients’ immune systems to combat and eradicate cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Apexigen
Confluence Life Sciences
HQ: United States
Website
- Description: Provider of rational drug design-based discovery and development of mechanistically novel kinase inhibitors for human and animal health care, targeting key signal transduction enzymes involved in regulating cancer growth and survival and modulating chronic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confluence Life Sciences company profile →
Inotrem
HQ: France
Website
- Description: Provider of immunotherapies targeting the TREM-1 pathway, including nangibotide, a synthetic peptide and first-in-class TREM-1 inhibitor for acute inflammatory syndromes (septic shock, severe COVID-19); a monoclonal antibody program for chronic inflammatory and fibrotic diseases and immuno-oncology; and a companion diagnostic with Roche Diagnostics measuring soluble TREM-1 in blood to identify septic shock patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inotrem company profile →
CytoImmune Therapeutics
HQ: United States
Website
- Description: Provider of engineered, allogeneic, tumor-reactive NK cell immunotherapies designed to attack cancer and stimulate immunity, including TRACK-NK medicines; off-the-shelf candidates CYTO NK-102 for NSCLC, CYTO NK-203 for PSCA+ solid tumors, CYTO NK-201 for FLT3 AML, and CYTO NK-301 for multiple myeloma; plus the Coalescent platform for triple-edited NK cells (CAR expression, soluble IL-15, BiKE secretion).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoImmune Therapeutics company profile →
Cytune Pharma
HQ: France
Website
- Description: Provider of novel immunotherapeutic agents primarily for cancer, developing a broad portfolio to restore and activate the immune system. Utilizes a proprietary immunology breakthrough based on an effective form of the human immunocytokine IL-15 via trans-presentation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytune Pharma company profile →
Flexus BioSciences
HQ: United States
Website
- Description: Provider of novel anti-cancer therapeutics created, developed, and commercialized through an innovative application of unexploited insights in immunology; privately-held biopharmaceutical company founded in 2013 and headquartered in San Carlos, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flexus BioSciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Apexigen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Apexigen
2.2 - Growth funds investing in similar companies to Apexigen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Apexigen
4.2 - Public trading comparable groups for Apexigen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →